Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana

FASEB Journal

Volumn 20, Issue 8, 2006, Pages

  Voss, Cristina ^a   Eyol, Ergül ^a   Frank, Martin ^a   Von Der Lieth, Claus W ^a   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer agent; Lectin; Liver metastasis model; Peroral activity; Plant protein

Indexed keywords

COMPLEMENTARY DNA; CYTOTOXIC FACTOR; DNA FRAGMENT; PLACEBO; PLANT EXTRACT; RIBOSOME INACTIVATING PROTEIN; RIPROXIMIN; TYPE 2 RIBOSOME INACTIVATING PROTEIN; ANTINEOPLASTIC AGENT; GALACTOSE; RIPROXIMIN PROTEIN, XIMENIA AMERICANA; VEGETABLE PROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL STRAIN MCF 7; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PURIFICATION; EXTRACTION; GENE AMPLIFICATION; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; ION EXCHANGE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN SYNTHESIS; RAT; SEQUENCE ANALYSIS; AFRICAN MEDICINE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG EFFECT; GLYCOSYLATION; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; OLACACEAE; STRUCTURAL HOMOLOGY; TUMOR CELL LINE;

XIMENIA AMERICANA;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; GALACTOSE; GLYCOSYLATION; HUMANS; MEDICINE, AFRICAN TRADITIONAL; MOLECULAR SEQUENCE DATA; OLACACEAE; PLANT PROTEINS; PROTEIN BIOSYNTHESIS; RATS; SEQUENCE ANALYSIS, PROTEIN; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 33845649761     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5231fje     Document Type: Article

References (39)

1. Voss, C., Eyol, E., and Berger, M. R. (2005) Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine. Toxicol. Appl. Pharmacol. (epub ahead of print, doi: 10.1016/j.taap. 2005.05.016)
2. Barbieri, L., Battelli, M. G., and Stirpe, F. (1993) Ribosome- inactivating proteins from plants. Biochim. Biophys. Acta 1154, 237-282
3. Stirpe, F. (2004) Ribosome-inactivating proteins. Toxicon 44, 371-383
4. Battelli, M. G. (2004) Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins. Mini. Rev. Med. Chem. 4, 513-521
5. Lord, M. J., Jolliffe, N. A., Marsden, C. J., Pateman, C. S., Smith, D. C., Spooner, R. A., Watson, P. D., and Roberts, L. M. (2003) Ricin. Mechanisms of cytotoxicity. Toxicol. Rev. 22, 53-64
6. Lin, J. Y., Tserng, K. Y., Chen, C. C., Lin, L. T., and Tung, T. C. (1970) Abrin and ricin: new anti-tumour substances. Nature 227, 292-293
7. Girbes, T., Ferreras, J. M., Iglesias, R., Citores, L., De Torre, C., Carbajales, M. L., Jimenez, P., De Benito, F. M., and Munoz, R. (1996) Recent advances in the uses and applications of ribosome-inactivating proteins from plants. Cell Mol. Biol. (Noisy-legrand) 42, 461-471
8. Kreitman, R. J. (2003) Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5, 44-51
9. Schoffski, P., Riggert, S., Fumoleau, P., Campone, M., Bolte, O., Marreaud, S., Lacombe, D., Baron, B., Herold, M., Zwierzina, H., Wilhelm-Ogunbiyi, K., Lentzen, H., and Twelves, C. (2004) Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann. Oncol. 15, 1816-1824
10. Schoffski, P., Breidenbach, I., Krauter, J., Bolte, O., Stadler, M., Ganser, A., Wilhelm-Ogunbiyi, K., and Lentzen, H. (2005) Weekly 24 h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours. Eur. J. Cancer 41, 1431-1438
11. Adam, K. P., and Becker, H. (2000) Peptide-Proteine. In Analytik biogener Arznei-stoffe (Adam, K. P., and Becker, H., eds) pp. 470-474, Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany
12. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4, 2411-2423
13. Konstantinov, S. M., Topashka-Ancheva, M., Benner, A., and Berger, M. R. (1998) Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer 77, 778-786
14. Langer, M., Rothe, M., Eck, J., Mockel, B., and Zinke, H. (1996) A nonradioactive assay for ribosome-inactivating proteins. Anal. Biochem. 243, 150-153
15. Wittmer, A., Khazaie, K., and Berger, M. R. (1999) Quantitative detection of lac-Z-transfected CC531 colon carcinoma cells in an orthotopic rat liver metastasis model. Clin. Exp. Metastasis 17, 369-376
16. Saenger, J., Leible, M., Seelig, M. H., and Berger, M. R. (2004) Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction. J. Cancer Res. Clin. Oncol. 130, 203-210
17. Kinter M., and Sherman N.E. (2000) An ingel digestion protocol. In Protein Sequencing and Identification using Tandem Mass Spectrometry (Desiderio, D. M., and Nibbering, M. M., eds) pp. 152-160, Wiley-Interscience, New York, U. S. A.
18. Perkins, D. N., Pappin, D. J., Creasy, D. M., and Cottrell, J. S. (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567
19. Kinter M., and Sherman N.E. (2000) Interpretation of the Product ion Spectra of Tryptic Peptides. In Protein Sequencing and Identification using Tandem Mass Spectrometry (Desiderio, D. M., and Nibbering, M. M., eds) pp. 81-114, Wiley-Interscience, New York
20. Eck, J., Langer, M., Mockel, B., Baur, A., Rothe, M., Zinke, H., and Lentzen, H. (1999) Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. Eur. J. Biochem. 264, 775-784
21. Marsden, C. J., Fulop, V., Day, P. J., and Lord, J. M. (2004) The effect of mutations surrounding and within the active site on the catalytic activity of ricin A chain. Eur. J. Biochem. 271, 153-162
22. Schwede, T., Kopp, J., Guex, N., and Peitsch, M. C. (2003) SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385
23. Hooft, R. W., Vriend, G., Sander, C., and Abola, E. E. (1996) Errors in protein structures. Nature 381, 272
24. Pontius, J., Richelle, J., and Wodak, S. J. (1996) Deviations from standard atomic volumes as a quality measure for protein crystal structures. J. Mol. Biol. 264, 121-136
25. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19, 1639-1662
26. Mishra, V., Bilgrami, S., Sharma, R. S., Kaur, P., Yadav, S., Krauspenhaar, R., Betzel, C., Voelter, W., Babu, C. R., and Singh, T. P. (2005) Crystal structure of himalayan mistletoe ribosome-inactivating protein reveals the presence of a natural inhibitor and a new functionally active sugar binding site. J. Biol. Chem. 280, 20712-20721
27. Hartley, M. R., Lord, J. M. (2004) Genetics of ribosome-inactivating proteins. Mini. Rev. Med. Chem. 4, 487-492
28. Deeks, E. D., Cook, J. P., Day, P. J., Smith, D. C., Roberts, L. M., and Lord, J. M. (2002) The low lysine content of ricin A chain reduces the risk of proteolytic degradation after translocation from the endoplasmic reticulum to the cytosol. Biochemistry 41, 3405-3413
29. Lord, J. M., Deeks, E., Marsden, C. J., Moore, K., Pateman, C., Smith, D. C., Spooner, R. A., Watson, P., and Roberts, L. M. (2003) Retrograde transport of toxins across the endoplasmic reticulum membrane. Biochem. Soc. Trans. 31, 1260 -1262
30. Rutenber, E., Ready, M., and Robertus, J. D. (1987) Structure and evolution of ricin B chain. Nature 326, 624-626
31. Rutenber, E., Katzin, B. J., Ernst, S., Collins, E. J., Mlsna, D., Ready, M. P., and Robertus, J. D. (1991) Crystallographic refinement of ricin to 2.5 A. Proteins 10, 240-250
32. Krauspenhaar, R., Eschenburg, S., Perbandt, M., Kornilov, V., Konareva, N., Mikailova, I., Stoeva, S., Wacker, R., Maier, T., Singh, T., Mikhailov, A., Voelter, W., and Betzel, C. (1999) Crystal structure of mistletoe lectin I from Viscum album. Biochem. Biophys. Res. Commun. 257, 418-424
33. Munoz, R., Arias, Y., Ferreras, J. M., Jimenez, P., Rojo, M. A., and Girbes, T. (2001) Sensitivity of cancer cell lines to the novel nontoxic type 2 ribosome-inactivating protein nigrin b. Cancer Lett. 167, 163-169
34. Pusztai, A., Grant, G., Gelencser, E., Ewen, S. W. B., Pfuller, U., Eifler, R., and Bardocz, S. (1998) Effects of an orally administered mistletoe (type-2 RIP) lectin on growth, body composition, small intestinal structure, and insulin levels in young rats. J. Nutr. Biochem. 9, 31-36
35. Pryme, I. F., Bardocz, S., Pusztai, A., Ewen, S. W., and Pfuller, U. (2004) A mistletoe lectin (ML-1)-containing diet reduces the viability of a murine non-Hodgkin lymphoma tumor. Cancer Detect. Prev. 28, 52-56
36. Barbieri, L., Ciani, M., Girbes, T., Liu, W. Y., Van Damme, E. J., Peumans, W. J., and Stirpe, F. (2004) Enzymatic activity of toxic and non-toxic type 2 ribosome-inactivating proteins. FEBS Lett. 563, 219-222
37. Girbes, T., Ferreras, J. M., Arias, F. J., Munoz, R., Iglesias, R., Jimenez, P., Rojo, M. A., Arias, Y., Perez, Y., Benitez, J., Sanchez, D., and Gayoso, M. J. (2003) Non-toxic type 2 ribosomeinactivating proteins (RIPs) from Sambucus: occurrence, cellular and molecular activities and potential uses. Cell Mol. Biol. (Noisy-le-grand) 49, 537-545
38. Citores, L., Munoz, R., Rojo, M. A., Jimenez, P., Ferreras, J. M., and Girbes, T. (2003) Evidence for distinct cellular internalization pathways of ricin and nigrin b. Cell Mol. Biol. (Noisy.-le-grand) 49 Online Pub, OL461-OL465
39. Battelli, M. G., Musiani, S., Buonamici, L., Santi, S., Riccio, M., Maraldi, N. M., Girbes, T., and Stirpe, F. (2004) Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. Cell Mol. Life Sci. 61, 1975-1984